Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INMD Stock Forecast 2025-2026
$13.34
Current Price
$845.11M
Market Cap
Buy 1
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to INMD Price Targets
+79.9%
To High Target of $24.00
+19.9%
To Median Target of $16.00
+4.9%
To Low Target of $14.00
INMD Price Momentum
-5.1%
1 Week Change
-8.2%
1 Month Change
-23.4%
1 Year Change
-20.1%
Year-to-Date Change
-32.8%
From 52W High of $19.85
+1.4%
From 52W Low of $13.16
📊 TOP ANALYST CALLS
Did INMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inmode is one of their latest high-conviction picks.
Latest INMD Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, INMD has a neutral consensus with a median price target of $16.00 (ranging from $14.00 to $24.00). The overall analyst rating is Buy (6.3/10). Currently trading at $13.34, the median forecast implies a 19.9% upside. This outlook is supported by 1 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 79.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INMD Analyst Ratings
1
Buy
6
Hold
0
Sell
INMD Price Target Range
Low
$14.00
Average
$16.00
High
$24.00
Current: $13.34
Latest INMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 30, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $24.00 |
| Apr 29, 2025 | Canaccord Genuity | Caitlin Cronin | Hold | Maintains | $15.00 |
| Apr 29, 2025 | UBS | Danielle Antalffy | Neutral | Maintains | $16.25 |
| Apr 29, 2025 | BTIG | Sam Eiber | Neutral | Downgrade | $0.00 |
| Apr 28, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Apr 14, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Apr 14, 2025 | Jefferies | Matthew Taylor | Hold | Maintains | $15.00 |
| Apr 9, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 5, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $29.00 |
| Feb 4, 2025 | Needham | Mike Matson | Hold | Maintains | $0.00 |
| Jan 9, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $26.00 |
| Oct 31, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Oct 21, 2024 | Alliance Global Partners | Buy | Initiates | $0.00 | |
| Oct 17, 2024 | BTIG | Sam Eiber | Buy | Initiates | $25.00 |
| Oct 14, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $27.00 |
| Oct 10, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Sep 27, 2024 | Raymond James | Outperform | Initiates | $0.00 | |
| Aug 22, 2024 | Scotiabank | Sector Outperform | Initiates | $0.00 | |
| Jul 23, 2024 | Jefferies | Matthew Taylor | Hold | Downgrade | $19.00 |
| Jul 15, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $29.00 |
InMode Ltd. (INMD) Competitors
The following stocks are similar to Inmode based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InMode Ltd. (INMD) Financial Data
InMode Ltd. has a market capitalization of $845.11M with a P/E ratio of 6.0x. The company generates $392.41M in trailing twelve-month revenue with a 44.8% profit margin.
Revenue growth is -3.0% quarter-over-quarter, while maintaining an operating margin of +20.1% and return on equity of +24.5%.
Valuation Metrics
Market Cap
$845.11M
Enterprise Value
$411.98M
P/E Ratio
6.0x
PEG Ratio
6.3x
Price/Sales
2.2x
Growth & Margins
Revenue Growth (YoY)
-3.0%
Gross Margin
+78.2%
Operating Margin
+20.1%
Net Margin
+44.8%
EPS Growth
-23.2%
Financial Health
Cash/Price Ratio
+55.9%
Current Ratio
8.7x
Debt/Equity
0.9x
ROE
+24.5%
ROA
+8.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
InMode Ltd. (INMD) Business Model
About InMode Ltd.
What They Do
Provides innovative medical technologies for aesthetics.
Business Model
InMode Ltd. designs and manufactures minimally invasive aesthetic healthcare solutions, generating revenue through the sale of advanced medical devices that utilize radiofrequency, light, and laser technologies. Their products are used in a variety of procedures, catering to the growing demand for effective and low-downtime aesthetic treatments.
Additional Information
Founded in Israel, InMode has a global presence, supplying its technologies to clinics and practitioners in multiple regions. The company is a significant player in the aesthetic medical device industry, focusing on non-invasive treatment options that enhance patient care and drive market growth.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
599
CEO
Mr. Moshe Mizrahy
Country
Israel
IPO Year
2019
Website
www.inmodemd.comInMode Ltd. (INMD) Latest News & Analysis
Latest News
Quick Summary
InMode Ltd. (Nasdaq: INMD) responded to DOMA Perpetual Capital Management's CEO regarding concerns raised in a public letter on May 9, 2025.
Why It Matters
InMode's communication with DOMA may indicate ongoing corporate governance issues or strategic disagreements, potentially affecting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program
1 month ago
Quick Summary
DOMA Perpetual Capital Management, a major shareholder of InMode Ltd. (NYSE: INMD), has urged the Board to resume stock buybacks and replace CEO Moshe Mizrahy.
Why It Matters
Calls for accelerated buybacks can boost share prices, while leadership changes may signal strategic shifts. Both factors impact investor confidence and stock performance for InMode.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
InMode Ltd. announced news from Irvine, California, on May 6, 2025. Further details regarding the announcement were not provided in the excerpt.
Why It Matters
InMode Ltd.'s announcement could signal developments affecting its market position, product offerings, or financial performance, influencing investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
InMode Ltd. (Nasdaq: INMD) will participate in BNP's 3rd Annual Aesthetics Day on May 19, featuring a virtual fireside chat at 11:00 am ET with CEO Moshe Mizrahy and CFO Yair Malca.
Why It Matters
InMode Ltd.'s participation in investor conferences highlights its commitment to transparency and engagement, potentially boosting investor confidence and interest in the stock.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
InMode Ltd. (NASDAQ: INMD) will hold its Q1 2025 earnings conference call on April 28 at 8:30 AM ET, featuring executives including CEO Miri Segal and CFO Yair Malca.
Why It Matters
InMode's Q1 2025 earnings call provides insights into its financial performance and strategic direction, impacting investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
InMode's Q1 2025 results missed revenue and EPS estimates, causing a 12% stock drop. Guidance may be cut; the rating is downgraded from Buy to Hold due to weakening demand and uncertain forecasts.
Why It Matters
InMode's Q1 2025 results miss estimates, causing a 12% stock drop and a downgrade to Hold. Weak demand and uncertain forecasts overshadow solid fundamentals, impacting investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About INMD Stock
What is InMode Ltd.'s (INMD) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, InMode Ltd. (INMD) has a median price target of $16.00. The highest price target is $24.00 and the lowest is $14.00.
Is INMD stock a good investment in 2025?
According to current analyst ratings, INMD has 1 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.34. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INMD stock?
Wall Street analysts predict INMD stock could reach $16.00 in the next 12 months. This represents a 19.9% increase from the current price of $13.34. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is InMode Ltd.'s business model?
InMode Ltd. designs and manufactures minimally invasive aesthetic healthcare solutions, generating revenue through the sale of advanced medical devices that utilize radiofrequency, light, and laser technologies. Their products are used in a variety of procedures, catering to the growing demand for effective and low-downtime aesthetic treatments.
What is the highest forecasted price for INMD InMode Ltd.?
The highest price target for INMD is $24.00 from Matt Miksic at Barclays, which represents a 79.9% increase from the current price of $13.34.
What is the lowest forecasted price for INMD InMode Ltd.?
Price targets from Wall Street analysts for INMD are not currently available. The stock is trading at $13.34.
What is the overall INMD consensus from analysts for InMode Ltd.?
The overall analyst consensus for INMD is neutral. Out of 11 Wall Street analysts, 1 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are INMD stock price projections?
Stock price projections, including those for InMode Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 3:30 AM UTC